XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
Shareholders' Equity
 3 Months Ended
Mar. 31, 2022
Stockholders' Equity Note [Abstract]  
Shareholders' Equity Shareholders’ Equity
Stock-Based Compensation
The Company has only non-qualified stock options and restricted stock units outstanding under its equity compensation plans. All outstanding stock options have performance-based vesting provisions specific to each option grant that tie the vesting of the applicable stock options to the Company’s financial performance. The Company’s stock options vest at a rate of 50% when a specified financial vesting target is achieved, and the remaining 50% when a second, higher specified financial vesting target is achieved. Options vest as a result of achievement of the financial vesting targets. Options
granted in December 2017 and thereafter include a service condition which requires a minimum two or four year waiting period from the grant date along with the attainment of the applicable financial vesting target. The targets are measured annually on December 31. The amount of stock-based compensation expense recognized in the period is based upon management’s estimate of when the financial vesting targets may be achieved. Any change in management’s estimate could result in the remaining amount of stock-based compensation expense to be accelerated, spread out over a longer period, or reversed. This may cause volatility in the recognition of stock-based compensation expense in future periods and could materially affect the Company’s earnings. The Company's restricted stock units outstanding vest ratably over four years commencing March 31, 2022.
The Company recognized stock-based compensation expense in its Consolidated Financial Statements in the three months ended March 31, 2022 and 2021, respectively, as follows: 
Three Months Ended March 31,
 20222021
Stock-based compensation expense$10,566 $9,752 
Less: Deferred tax benefit(2,096)(1,854)
Stock-based compensation expense, net of tax$8,470 $7,898 
As of March 31, 2022, there was approximately $92,057 of unrecognized compensation cost remaining related to unvested employee stock options that management expects will vest and is being amortized.
The Company issues new common shares associated with the exercise of stock options. The total intrinsic value of options exercised during the three months ended March 31, 2022 was $8,966. The total options exercisable as of March 31, 2022 had an intrinsic value of $103,527. The total intrinsic value for options exercisable is calculated as the difference between the market value of the Company’s common stock as of March 31, 2022 and the weighted average exercise price of the options. The market value of the Company’s common stock as of March 31, 2022 was $60.21 as reported by the Nasdaq Stock Market, LLC. The weighted average exercise price of the options exercisable as of March 31, 2022 was $49.16. Total options that were outstanding as of March 31, 2022 were 18,467,000. Total options that were exercisable as of March 31, 2022 were 8,153,000.
Common Stock Buyback
The Company’s Board of Directors, under multiple authorizations, has authorized the repurchase of common stock on the open market or through private transactions. The Company purchased 1,713,000 shares at a total cost of $100,090 during the three months ended March 31, 2022, which reduced the total shares outstanding of common stock. The cost of stock purchases during the period includes the cost of certain transactions that settled in the following quarter. As of March 31, 2022, the Company had approximately $131,203 of authorization remaining for the purchase of common stock under the program.
The Company immediately retires its common stock when purchased. Upon retirement, the Company reduces Capital in excess of par value for the average capital per share outstanding and the remainder is charged against Retained earnings. If the Company reduces its Retained earnings to zero, any subsequent purchases of common stock will be charged entirely to Capital in excess of par value.